Skip to main content

Table 5 Change in total discounted lifetime costs (2010 US$) and quality adjusted life years of boceprevir-based regimens compared with PR48 in multi-way sensitivity and subset analyses

From: Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

  BOC/RGT vs. PR48 BOC/PR48 vs. PR48
  Discounted costs Discounted QALYs ICER Discounted costs Discounted QALYs ICER
Base 10,348 0.62 16,792 35,727 0.65 55,162
Sensitivity Analyses       
Discount rate for costs = 0%, discount rate for utilities = 0% 2,868 1.23 2,338 27,870 1.33 21,016
Discount rate for costs = 5%, discount rate for utilities = 5% 12,894 0.42 30,630 38,256 0.43 88,789
Lower Bound of Transition Rates 12,126 0.43 28,314 37,703 0.44 85,867
Upper Bound of Transition Rates 11,032 0.83 13,340 36,485 0.88 41,393
Lower Bound for Health State Costs 12,538 0.62 20,346 38,165 0.65 58,927
Upper Bound for Health State Costs 8,158 0.62 13,239 33,288 0.65 51,397
Lower Bound for Population Average Utilities 10,348 0.61 17,097 35,727 0.64 56,228
Upper Bound for Population Average Utilities 10,348 0.63 16,508 35,727 0.66 54,133
Lower Bound for On Treatment Utilities 10,348 0.62 16,724 35,727 0.64 56,120
Upper Bound for On Treatment Utilities 10,348 0.62 16,819 35,727 0.66 53,800
Lower Bound for Utilities of SVR states 10,348 0.31 33,511 35,727 0.30 117,395
Upper Bound for Utilities of SVR states 10,348 0.62 16,792 35,727 0.65 55,162
Lower Bound for Health State Utilities 10,348 0.95 10,906 35,727 1.02 34,927
Upper Bound for Health State Utilities 10,348 0.33 31,124 35,727 0.33 108,965
Subset Analyses       
Non-Black Cohort 9,655 0.64 15,067 35,968 0.64 56,013
Black Cohort 14,437 0.47 30,627 34,305 0.68 50,423
  BOC regimen vs. PR48    
  Discounted Costs Discounted Utilities ICER    
Label-Based Analyses 18,046 0.66 27,265    
  1. PR48 – peginterferon-ribavirin regimen for 48 weeks; BOC/RGT – peginterferon–ribavirin for 4 weeks followed by peginterferon-ribavirin and boceprevir for 24 weeks, and those with a detectable hepatitis C virus (HCV) RNA level between weeks 8 and 24 received peginterferon–ribavirin from week 28 to week 48; BOC/PR48 –peginterferon–ribavirin for 48 weeks and boceprevir for 44 weeks.